New Psychedelic Research Nonprofit Teams with Johns Hopkins University for Real-World Study on Use of Psilocybin MushrooPharmaDrug Inc. Enters into Definitive Agreement to Acquire First Smart Shop in the NetherlandsCybin Corp. Is A Multi-Faceted Life Sciences Company Investors Should Have On Their RadarMindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic WellneNovamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.Psychedelic Assisted Therapy Is Becoming A Very Real Alternative Method To Treat Mental IllnessNuminus and Together We Can Partner to Support Addiction Recovery and Mental WellnessMydecine Innovations Group Inc. Appoints Previous Red Bull Sports Marketing Director Jim Gunning as CMOGood2Go Corp. and Magical Brands Inc. Announce Update to Proposed Qualifying TransactionThe Psychedelic Legalization Movement Is In Full BloomNuminus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4.05 MillionNuminus Wellness Is Putting Key Pieces In Place To Drive Cutting Edge Research In The Field Of PsychedelicsMagicMed Industries Inc. Announces Brokered Private Placement with Mackie Research Capital CorporationCybin Corp. Announces Proposed Management Team and Board of Directors of the Resulting IssuerMydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading EuropeanWill Psychedelics Take The Same Trip Down The Road To Legalization As The Cannabis Industry?PharmaDrug Inc. Proposes a Strategic Mutual Investment with Red Light Holland Corp.Pure Extracts Has Significant Leverage To Both The Cannabis and Psychedelic SectorsRritual Mushrooms Is Here to Enhance You Daily “Ritual”MagicMed Industries Files First Psychedelic Derivative Patent
Back

MagicMed Industries Files First Psychedelic Derivative Patent

Jul 9, 2020 • 5:58 PM EDT
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

MagicMed Industries Inc. (“MagicMed” or “the Company”) today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering composition of matter, drug formulation and process of preparation claims for novel psilocybin derivatives.  This patent filing is anticipated to be the first in a series of applications that together will protect the Company’s broad portfolio of novel psilocybin molecular derivatives, the PsybraryTM.

MagicMed partners will be able to search, select and test from the derivatives in the PsybraryTM and use it as a building block for their own product development based on the indication that they are targeting (anxiety, depression, addiction, PTSD and many others).

“We are excited by the new opportunities to partner with pharmaceutical manufacturers afforded by the library of derivatives that this patent application claims,” stated MagicMed President and CEO Dr. Joseph Tucker. “Our business model is to work hand in hand with pharma partners to assist them in taking excellent medicinal product candidates forward.  In fact, we have already initiated talks with potential partners to assist them in the development of new therapies for diverse psychological indications.”

About Psilocybin
Psilocybin is a naturally occurring molecule that is generating significant interest as a component of potential new therapeutic medicinal products for inadequately treated psychological indications including anxiety, depression, substance dependence and cluster or migraine headaches. The potential medical application of psilocybin while encouraging, remains limited due to the natural molecule’s inherent side effects, such as hallucinations and panic attacks.  This has pointed to the need for modified molecules, which maximize positive attributes and reduce negative side effects.

About MagicMed
MagicMed Industries intends to partner with pharmaceutical and other companies to develop psychedelic-derived medicinal and licit consumer goods products.  MagicMed’s molecular derivatives library, the PsybraryTM is anticipated to be an essential building block from which industry can develop new patented products.  The initial focus of the PsybraryTM is on psilocybin, which is expected to be opportunistically expanded to other psychedelics like MDMA, ketamine, Ibogaine, Mescaline, and Ayahuasca.  For more information, please visit our website at www.magicmedindustries.com.

Forward Looking Statements 

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions and accordingly, actual results and future events could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. All statements other than statements of present or historical fact are forward-looking statements, including statements with respect to MagicMed’s future business plans and partnerships, the anticipated uses of MagicMed’s patents and the development of the PsybraryTM. Forward-looking statements include words or expressions such as “proposed”, “anticipated”, “will”, “subject to”, “near future”, “in the event”, “would”, “expect”, “prepared to” and other similar words or expressions.

Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. Some of the risks and other factors could cause results to differ materially from those expressed in the forward-looking statements which include, but are not limited to: the ability of MagicMed to secure patent protection; the ability of MagicMed to enter into partnership agreements or other arrangements; unforeseen challenges in carrying out the business plans of MagicMed; trends in the future use of psilocybin; general business, economic, competitive, political and social uncertainties; the state of capital markets; and other unforeseen events, developments, or factors causing any of the aforesaid expectations, assumptions, and other factors ultimately being inaccurate or irrelevant. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We disclaim any obligation to update or revise these forward-looking statements, except as required by applicable law.

SOURCE MagicMed Industries Inc.

Related Links

https://magicmedicine.net/

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link